An Evolving Frontier: Endometrial Cancer Treatment-Disparities in Endometrial Cancer Outcomes, What More Can We Do?

Disparities in Endometrial Cancer Outcomes, What More Can We Do?

Video Transcription

Video Summary

Dr. Anna Fagotti presented on disparities in endometrial cancer outcomes, emphasizing the need for improved diversity, equity, inclusion, and access to clinical trials. Endometrial cancer is globally rising, particularly in low and middle-income countries, with distinct regional incidence and mortality rates. Disparities exist, notably in the U.S., where black women experience higher mortality rates across all stages compared to white women. Factors like income, education, insurance type, and tumor characteristics contribute to these disparities, which are often preventable. Clinical inequalities manifest in delayed diagnoses, fewer minimally invasive treatments, and higher refusal rates for chemotherapy among black women. Marginalization further exacerbates these disparities. Molecular differences between ethnicities highlight the need for tailored treatments. Efforts to reduce disparities include lifestyle interventions, molecular-driven treatments, and educational initiatives to boost clinical trial participation. Ensuring minority representation in clinical trials is crucial for equitable treatment advancement.

Keywords

endometrial cancer

disparities

clinical trials

mortality rates

molecular differences

equitable treatment